Effects and efficacy: Benazepril can be used to treat hypertension and congestive heart failure. It is used as an adjunctive treatment for patients with congestive heart failure (NYHA grade II-IV) who do not respond well to digitalis and/or diuretics.
Usage and dosage: Benazepril is mainly used orally. The specific dosage should be prescribed by the doctor and adjusted by the doctor according to the antihypertensive effect. When patients with hypertension who do not use diuretics start treatment, the recommended daily dose of benazepril is 10 mg, once a day. If the effect is not good, it can be increased to 20 mg per day. The dosage must be adjusted according to the response of blood pressure, usually every 1 to 2 weeks. For some patients, the antihypertensive effect may be weakened at the end of the dosing interval. For such patients, the total daily dose should be divided into two doses, or a diuretic should be added. The maximum recommended daily dose of this product for the treatment of hypertension is 40 mg, taken once or twice. If taking this product alone cannot control blood pressure, a diuretic can be added according to the doctor's advice. Patients with creatinine clearance ≥30ml/min can take the usual dose. For patients with blood pressure <30ml/min, the initial daily dose is 5mg, and if necessary, the dose can be increased to 10mg/day. If further blood pressure reduction is still required, a diuretic or another antihypertensive drug can be added. Congestive heart failure This product is suitable for adjuvant treatment of patients with congestive heart failure. The recommended initial dose is 2.5mg, once a day. Due to the risk of a sharp drop in blood pressure after the first dose, patients need to be closely monitored when taking this product for the first time. As long as the patient does not experience symptomatic hypotension and other unacceptable adverse reactions, and the symptoms of heart failure are not effectively relieved, the dose can be adjusted to 5mg once a day after 2 to 4 weeks. Depending on the patient's clinical response, the dose can be adjusted to 10mg once a day or even 20mg once a day at appropriate time intervals. This product is effective once a day. For some patients, the response may be better if the daily dose is divided into two doses. Controlled clinical studies have shown that patients with severe heart failure (NYHA grade IV) require a smaller dose than patients with mild and moderate heart failure (NYHA grade II to III). When the creatinine clearance of patients with heart failure is less than 30ml/min, the daily dose can be increased to a maximum of 10mg, but a lower initial dose (such as 2.5mg) may be more ideal. When the creatinine clearance of patients with heart failure is less than 30ml/min, the daily dose can be increased to a maximum of 10mg, but a lower initial dose (2.5mg) may be sufficient.
Drug contraindications:
Allergic to this product is prohibited. Driving is prohibited during pregnancy. Use with caution
Related dosage forms:
Tablets, capsules
Effects and efficacy:
Carboplatin injection is a second-generation platinum anti-tumor drug, which has certain effects on ovarian cancer, small cell lung cancer, non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal cancer, testicular cancer, seminoma, bladder cancer, mesothelioma, pediatric brain tumors, etc. This product is a non-specific anti-tumor drug for the cycle, which directly acts on DNA, thereby inhibiting tumor cells with vigorous division.
Usage and dosage:
This product can be used alone or in combination with other anti-cancer drugs. Before use, add this product to 250-500ml of 5% glucose injection for dilution. For intravenous infusion, the recommended dose is calculated based on 0.3-0.4g/m2 or AUC per body surface area, a single dose, or five doses for 5 days, repeated every 3-4 weeks, and 2-4 cycles as a course of treatment. The dose after the first dose needs to be adjusted according to the white blood cell and platelet counts after the medication. Please follow the doctor's advice for details.
Adverse reactions:
Common adverse reactions Myelosuppression is a dose-related toxicity. After a single dose, white blood cells and platelets reach their lowest point 21 days after medication, and usually recover around 30 days after medication; the lowest point of granulocytes occurs 21 to 28 days after medication, and usually recovers around 35 days; white blood cell and platelet reduction is dose-related and has an accumulation effect. Pain at the injection site. Case data and post-marketing experience show that about 15% of patients experience nausea without vomiting after treatment with carboplatin, 65% experience vomiting, and 1/3 of them have severe vomiting; this product also has a certain degree of nephrotoxicity. The incidence and severity of nephrotoxicity may increase in patients with impaired renal function before treatment. Less common adverse reactions Allergic reactions (rash or itching, occasionally wheezing), which occur within a few minutes after use; peripheral neurotoxicity, numbness or tingling of fingers (toes), with cumulative effects; ototoxicity, high-frequency hearing loss occurs first, tinnitus is occasionally seen; blurred vision, mucositis or stomatitis; constipation or diarrhea, lack of appetite, etc. In addition, you may experience other side effects. If you feel unwell after taking the medicine, please inform the doctor in time. The doctor will determine whether to stop taking the medicine or take necessary measures according to the severity of the adverse reaction.
Drug contraindications:
Allergic to this product is prohibited. It is prohibited for liver and kidney dysfunction. It is prohibited to use it with caution during pregnancy and lactation.
Inositol Nicotinate Tablets are Western medicines and peripheral vasodilators used as adjuvant treatments for hyperlipidemia, atherosclerosis, and various peripheral vascular disorders.
Hyperlipidemia: When the levels of cholesterol (CH), triglycerides (TG), and low-density lipoprotein cholesterol (LDL-C) in serum are elevated and the levels of high-density lipoprotein cholesterol (HDL-C) are reduced, this product can be considered for dilating blood vessels and reducing lipids.
Atherosclerosis: When lipids and necrotic tissues continue to accumulate in the endothelium of arterial vessels and form plaques with a yellow porridge-like appearance, headaches, dizziness, vomiting, chest tightness, cold or numbness of the lower limbs, etc. can occur. This product can be used as an adjuvant treatment to improve physical discomfort.
Various peripheral vascular disorders: such as occlusive arteriosclerosis, acromial artery spasm, frostbite, vascular migraine, etc.
يعد هذا المنتج أحد الأدوية الرئيسية في بروتوكولات MOPP وCOPP القياسية لعلاج سرطان الغدد الليمفاوية الخبيثة. كما أن له تأثيرات معينة على SCLC، والورم الميلانيني الخبيث، والورم النقوي المتعدد، وأورام المخ (الابتدائية أو الثانوية)، وما إلى ذلك.
Effects and efficacy:
This product is used in combination with prednisone or prednisolone to treat metastatic castration-resistant prostate cancer (mCRPC) and newly diagnosed high-risk metastatic endocrine-sensitive prostate cancer (mHSPC), including those who have not received endocrine therapy or have received endocrine therapy for no longer than 3 months.
Usage and dosage:
The recommended dose of this product is 1000mg (4×250mg tablets) orally once a day. This product is used in combination with prednisone or prednisolone 5mg orally twice a day to treat patients with metastatic castration-resistant prostate cancer (mCRPC). This product is used in combination with prednisone or prednisolone 5mg orally once a day to treat newly diagnosed high-risk metastatic endocrine-sensitive prostate cancer (mHSPC). Patients receiving this product should also receive gonadotropin-releasing hormone analogs (GnRHa) or should have undergone bilateral orchiectomy. This product should be taken on an empty stomach at least 1 hour before and at least 2 hours after meals. This product should be swallowed whole with water. Do not break or chew it.
Adverse reactions: This product may cause hypertension, hypokalemia and retention. The most common adverse reactions in clinical practice are peripheral edema, hypokalemia, hypertension and urinary tract infection. Other important adverse reactions include heart disease, liver toxicity, fractures and allergic alveolitis. Usually, the adverse reactions of mineralocorticoids can be effectively controlled after treatment. The combined use of corticosteroids can reduce the incidence and severity of these adverse drug reactions.
Drug contraindications:
Allergic to this product is contraindicated. It is contraindicated during pregnancy and lactation.
Effects and efficacy:
Adefovir dipivoxil is suitable for the treatment of adult chronic hepatitis B patients with evidence of active replication of hepatitis B virus, accompanied by persistent elevation of serum aminotransferase (ALT or AST) or liver function compensation with active histological lesions of the liver. This product can be used to alleviate organ physiological changes caused by viral replication, such as diseases that affect liver cell damage and liver function damage or abnormalities after chronic hepatitis B. In addition, Adefovir dipivoxil has clinical experience in treating AIDS.
Dosage and administration:
Patients must use Adefovir dipivoxil under the guidance of a physician with experience in treating chronic hepatitis B. Usage: Oral, before or after meals. Food does not affect the pharmacokinetics of Adefovir. Dosage: The recommended dose of Adefovir dipivoxil for adults (18-65 years old) is 1 tablet once a day. The optimal course of treatment has not yet been determined, and do not exceed the recommended dose. Please follow the doctor's advice for medication details. Patients should regularly monitor hepatitis B biochemical indicators, virological indicators and serum markers at least once every 6 months. Mild renal impairment (creatinine clearance ≥ 50ml/min) has little effect on the metabolism of adefovir dipivoxil. Patients with moderate and severe renal impairment (creatinine clearance < 50ml/min) or patients with end-stage renal disease need hemodialysis and adjustment of medication intervals. Moderate and severe liver damage has little effect on the pharmacokinetics of adefovir dipivoxil and does not require dosage adjustment.
Drug contraindications:
Athletes who are allergic to this product should not use it with caution
Related dosage forms:
Capsules, tablets
Effects and efficacy:
The main effect of stilbestrol tablets is to maintain the production of endogenous progesterone and chorionic gonadotropin in the human body and promote their secretion. It can be used in various periods of pregnancy, such as threatened abortion in early pregnancy, habitual abortion, mainly before the fifth month of pregnancy, and threatened premature birth in late pregnancy.
Usage and dosage:
The medication method and dosage of this product for threatened abortion, habitual abortion and threatened premature birth are different. Be sure to take the medicine according to the doctor's instructions. During use, the drug may cause changes in blood sugar, so pay attention to monitoring blood sugar, especially for patients with diabetes during pregnancy. Pay attention to monitoring blood sugar. Threatened abortion 1-3 tablets/day, continue to use the medicine for 5-7 days or until the symptoms disappear. The dose can be increased if necessary. Habitual abortion should be used immediately after the pregnancy is confirmed, and 1-2 tablets should be taken daily until one month after the crisis period, usually until the end of the fifth month of pregnancy. The dose for threatened premature birth needs to be individualized, usually higher than the above dose (10-20mg/day).
Adverse reactions:
Occasionally, fluid retention, nausea and headache may occur.
Contraindications:
Contraindicated in patients with allergic reaction to this product or those with impaired liver and kidney function.
Functional Indications:
Used to treat type 2 diabetes. 1. Monotherapy: This product is used as an auxiliary treatment for diet control and exercise to improve blood sugar control in patients with type 2 diabetes. 2. Use in combination with metformin hydrochloride: When metformin hydrochloride alone cannot effectively control blood sugar, this product can be used in combination with metformin hydrochloride to improve blood sugar control in patients with type 2 diabetes on the basis of diet and exercise. 3. Important usage restrictions: Since the effectiveness against type 1 diabetes and diabetic ketoacidosis has not been determined, this product is not intended for use in patients with type 1 diabetes or diabetic ketoacidosis.
Dosage:
Alogliptin Benzoate Tablets: 1. Recommended dosage: The recommended dosage of this product is 25 mg once a day. This product can be taken with food or separately. 2. Patients with impaired renal function: (1) Patients with mild renal impairment (creatinine clearance: CrCl≥60mL/min) do not need to adjust the dose when using this product. (2) For patients with moderate renal impairment (creatinine clearance: 30≤CrCl<60mL/min), the dosage of this product is 12.5 mg once a day. (3) For patients with severe renal impairment (creatinine clearance: 15≤CrCl<30mL/min) or end-stage renal failure (ESRD) (CrCl<15mL/min or requiring hemodialysis), the dosage of this product is 6.25mg Once a day. Dialysis time does not need to be considered when using this product. This product has not been studied in patients receiving peritoneal dialysis. (4) Since the dosage of this product needs to be adjusted according to renal function, it is recommended to evaluate renal function before starting treatment and review it regularly.
Adverse reactions:
Alogliptin Benzoate Tablets: 1. Please refer to the instructions for details of common adverse reactions in foreign clinical experience. 2. Post-marketing experience: The adverse reactions identified during the post-marketing use of this product outside the United States came from spontaneous reports from people of unknown size. Therefore, it is impossible to accurately estimate their frequency of occurrence or determine the causal relationship with the medication. Hypersensitivity reactions include anaphylaxis, angioedema, rash, urticaria, and severe cutaneous adverse reactions; elevated liver enzymes; fulminant hepatic failure and acute pancreatitis.
Medication contraindications:
Patients with a history of serious allergic reactions to alogliptin products, including patients who have developed anaphylaxis, angioedema, or severe adverse skin reactions.
Effects and efficacy: Unstable angina, acute myocardial infarction, local ischemic cerebrovascular disorder, etc. Aspirin is needed to inhibit platelet adhesion and aggregation, but the patient cannot tolerate the gastrointestinal reaction of aspirin.
Usage and dosage: Oral, usually once a day for adults, 1 tablet at a time; up to 4 tablets at a time depending on the condition.
Adverse reactions: Digestive system reactions manifest as nausea, vomiting, upper abdominal discomfort, abdominal pain, gastrointestinal ulcers, swollen lips, etc. Central nervous system reactions are mainly dizziness, excitement, headache, tinnitus and hearing loss. Allergic reactions manifest as rash, itching, asthma, angioedema, shock, etc., which can cause death in severe cases. Once an allergic reaction is found, seek medical attention in time. Other adverse reactions include dyspnea, low blood pressure, rhinitis, nosebleeds, etc. Once the above adverse reactions occur, it is recommended to seek medical attention in time.
Drug contraindications: Allergic to this product is prohibited. It is prohibited during pregnancy. It is prohibited for infants under 6 months old. Use with caution during lactation. Use with caution in liver and kidney dysfunction